BBI Solutions launches innovative conjugate blocking technology for lateral flow immunoassays

BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September.

BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September. The technology, developed in-house by BBI Solutions scientists, improves the limit of detection of an assay, providing an increase in sensitivity of up to ten times and a faster time to result.


Lateral flow immunoassays (LFIs) rely on the specific interaction between the analyte of interest and an immobilised binding partner, such as an antibody, antigen or enzyme. To improve performance, a ‘blocking' agent is bound to unoccupied conjugation sites on the reporter label, preventing non-specific binding. However, the most commonly used conjugate blocker, BSA cross-reacts with human serum albumin-binding antibodies, bovine and other animal-origin targets, and exhibits lot-to-lot variability. Its relatively large size can also lead to steric hindrance affecting the detection of the target molecule. The proprietary Morffi technology overcomes these issues1. Due to its size in comparison to BSA, it improves the availability of analyte-specific binding partners on the surface of the reporter label, increasing the signal intensity and sensitivity of the assay. Morffi has been successfully tested with over 30 conjugates to date, clearly demonstrating its suitability for a range of LFIs. Find out more in the BBI Solutions whitepaper entitled Morffi, Enhanced performance of a lateral flow assay.

1 Morgan West, Ffion Walters, Shaun Phillips and Darren Rowles; Enhanced performance of a lateral flow assay. Use of a novel conjugate blocking technology to improve performance of a gold nanoparticle-based lateral flow assay. http://bit.ly/morffiwhitepaper


About BBI Solutions
BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in-vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions offer lateral flow development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

BBI Solutions is part of the BBI Group.

www.bbisolutions.com

Featured Product

US Digital - E4T Miniature Optical Kit Encoder

US Digital - E4T Miniature Optical Kit Encoder

US Digital is pleased to announce the launch of the E4T, their latest series of miniature high performance optical encoders. The E4T series delivers a marked performance increase over similar encoder models and designed to be an enhanced replacement for the E4P encoder series. The E4T utilizes state of the art transmissive optical sensing technology, and incorporates US Digital's own proprietary OptoASIC. Assembly of the E4T is simple and efficient and retains the previous E4P's form factor. Key features of the new E4T include: • Mechanically and Electrically Interchangeable with E4P • Improved Quadrature Signal Strength • 100 kHz Frequency Response • Transmissive Optical Design • Collet Style Push on Optical Disk Design (Patent Pending) • Simple & Efficient Assembly Process As with all of our products the E4T is designed and manufactured in their Vancouver, Washington USA facility and is available for purchase as of December 2014.